Clinical Trial Update: Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ipilimumab and nivolumab with or without encorafenib and binimetinib in unresectable stage III or stage IV melanoma; currently active b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Braftovi (encorafenib) (encorafenib)
• Mektovi (binimetinib) (binimetinib)
• Opdivo (nivolumab) (nivolumab)
• Yervoy (Ipilimumab) (Ipilimumab)

Snippet

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC | Conditions: Unresectable Stage III Melanoma, Stage IV Melanoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING